Ortho Development

Ortho Development

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $20M

Overview

Ortho Development is a well-established, privately-held medical device company specializing in hip and knee arthroplasty solutions. With over 30 years in operation, it has built a portfolio of commercialized implant systems and maintains a strong focus on surgeon education and peer collaboration through its Center of Excellence and fellowship training programs. The company operates a direct sales and distribution model in the US and demonstrates a commitment to social impact through medical missions and donations. Its strategy centers on combining proven clinical success with technological innovation in a competitive joint reconstruction market.

OrthopedicsMusculoskeletal Disorders

Technology Platform

Integrated orthopedic implant design and manufacturing platform utilizing advanced material science, precision engineering, and surgeon-focused educational programs to drive clinical adoption and outcomes.

Funding History

2
Total raised:$20M
Series A$18M
Seed$2M

Opportunities

The aging global population and rising prevalence of osteoarthritis provide a strong, growing demand for joint replacement procedures.
Ortho Development can capitalize on this by leveraging its surgeon education programs to build loyalty and drive adoption of its innovative implant systems, potentially expanding into adjacent joint markets or digital surgery tools in the future.

Risk Factors

The company faces intense competition from larger, well-resourced medical device giants and is susceptible to changes in healthcare reimbursement policies that can affect procedure volumes.
Its focused product portfolio in hips and knees also creates concentration risk if market dynamics shift or product issues arise.

Competitive Landscape

Ortho Development competes in the large joint reconstruction market dominated by multinational giants like Stryker, Zimmer Biomet, and Johnson & Johnson's DePuy Synthes. Its competitive strategy relies on a focused product portfolio, deep surgeon relationships, and value-added educational services rather than competing on scale alone, positioning it as a nimble, partner-oriented alternative.